What Is Motor Neuron Disease?

An Essay on Lou Gehrig’s Disease, Anterior Horn Cells, and the Streetlight They Were Killed Beneath

Author’s Note

This essay operates in two registers. When examining establishment epidemiology, pharmaceutical trial data, and institutional admissions, it uses establishment terminology to prosecute the establishment’s own case against itself. When stating what is actually happening in the body, it shifts to terrain language. The reader should know which voice is operating: the former demonstrates that the cause is not unknown to those who have looked; the latter explains what they found.

---

The Door and the Room

Lou Gehrig was born in Yorkville, Manhattan in 1903.¹ He played 2,130 consecutive games for the New York Yankees, hit 493 home runs, and was the cleanup hitter in the most celebrated baseball lineup ever assembled. He began stumbling at thirty-five. He withdrew from baseball at thirty-six. He was dead at thirty-seven.

The Mayo Clinic gave the diagnosis a name that already existed — Jean-Martin Charcot had named it amyotrophic lateral sclerosis in 1869, shortly after he had also named multiple sclerosis.² The American public couldn’t pronounce it. So they renamed it after the patient. Then they closed the file on what killed him.

Eighty-five years later, the official answer remains: cause unknown.

Christopher Shaw is a neuroscientist at the University of British Columbia. In the early 2000s, his laboratory was studying the famous ALS cluster on Guam and looking for a second cluster that could narrow the search for causation. They found one in Gulf War veterans, whose ALS incidence ran significantly higher than the general population at significantly younger ages.³ The correlation held even in soldiers who had been vaccinated in preparation for deployment but had never actually deployed — which ruled out oil well fires, depleted uranium, nerve agents, and every other battlefield exposure. What every sick soldier had received was the anthrax vaccine.

BioPort, the manufacturer, refused to sell Shaw the vaccine. He looked at the listed ingredients and tested the two adjuvants most plausibly implicated: aluminum hydroxide and squalene. He injected young male mice with weight-adjusted doses and compared them to saline controls.

The aluminum-treated mice developed progressive motor dysfunction. Histological examination showed neuronal death in the motor neurons of the spinal cord and motor cortex. A second study using slightly older mice produced the same outcome and additionally documented aluminum located inside the motor neurons themselves, along with activation of the brain’s resident immune cells (microglia) at the site of neuron death.⁴

The paper is titled Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. It was published in the Journal of Inorganic Biochemistry in 2009.

The institutions tell the public the cause is unknown. A laboratory in Vancouver predicted from epidemiology, isolated the agent, ran the experiment, and produced the disease in mice.

Support This Work

This work remains free because paid subscribers make it possible. If you find value here, consider joining them.

Paid subscribers get access to all books — including The DMSO Book, The Kitchen Remedies Guide, Chlorine Dioxide, The PSA Trap, Breast Cancer, and more — with 1-2 new books added each month. Plus the Deep Dive Audio Library: 180+ in-depth audio book summaries and discussions.

Paid subscribers also get the Questions for Your Doctor series, short printable guides built around the questions doctors are not trained to answer, one decision at a time. The companion Before You Consent series goes deeper, walking through a single diagnosis or prescription from the moment it lands to the days after, with every figure sourced. And the Package Insert series reads the labels the doctor never opens and the pharmacist never mentions, what the manufacturer admits, in their own words, about what they sell.

I do this work independently, outside the institutions these books so often describe. No foundation grants, no academic approval, no editorial gatekeepers deciding what’s acceptable to publish. Your subscription makes that independence possible.

---

What the Establishment Says

The Mayo Clinic’s public-facing page on amyotrophic lateral sclerosis tells the reader: “The exact cause of the disease is still not known.”⁵ The National Institute of Neurological Disorders and Stroke uses the same formulation. The ALS Association states it plainly on its risk-factors page: “The exact cause of ALS is largely unknown.”⁶ The MND Association in the United Kingdom is more candid still: “The evidence gained in these studies has often been conflicting and clear conclusions cannot be given. With these limits, it is not yet possible to provide guidance on how to reduce the risk of developing MND.”⁷

The establishment divides cases into two categories. About ninety percent are called “sporadic” — meaning no family history. The remaining ten percent are called “familial” because the disease has appeared in more than one family member, which the establishment attributes to inherited genetic mutations. Within those familial cases, four named genes (C9orf72, SOD1, TARDBP, FUS) account for roughly seventy percent. Seventy percent of ten percent is seven percent of total cases.⁸ The genetic mutations the establishment has named account for approximately seven cases in every hundred. The other ninety-three are unexplained even within the framework the establishment uses.

The terrain framework reads the family clustering differently. Families share more than DNA. They share diets, household chemical exposures, dental amalgams, water sources, electromagnetic environments, and — in the modern era — vaccination schedules administered by the same providers in the same intervals. A “familial” case is a family with a shared exposure profile across decades. The genetic interpretation forecloses environmental investigation by declaring the cause innate. Even the establishment’s own figures cannot defend that closure: ninety-three cases in every hundred remain unexplained at any molecular level it will commit to, and the seven that are “explained” rest on the assumption that finding a gene variant correlated with the disease is the same as finding a cause.

The condition strikes roughly one to two new cases per hundred thousand people per year. The United States National ALS Registry’s mean estimate is 7.7 per hundred thousand in prevalence, with the upper bound at 9.9.⁹ In the United Kingdom, lifetime risk runs around one in three hundred. Around five thousand adults in the UK are living with the diagnosis at any one time; in Australia, about two thousand. Median age of onset sits between fifty-five and sixty-five. Half of patients die within fourteen to eighteen months of diagnosis. Some live a decade or longer. Cause of death is usually respiratory failure as the diaphragm fails.

The FDA has approved four ALS drugs in thirty years. None reverses the disease. None stops it. None substantially slows it.

Riluzole was approved in 1995. The trial data show patients on the drug lived about ten weeks longer than patients on a sugar pill — roughly 15.5 months versus 13.2 months from diagnosis to death.¹⁰ Cost runs from hundreds to thousands of dollars per year.

Edaravone (Radicava) was approved in 2017. It produced a measurable benefit only in a narrow group of early-stage Japanese patients, and the benefit was small — a 2.49-point change on a 48-point scale that doctors use to track how well a patient can do everyday tasks like swallowing, walking, and breathing.¹¹ European regulators looked at the same evidence and refused to approve the drug. In the United States, it costs around $146,000 a year.

Relyvrio was approved in September 2022 over the objections of the FDA’s own scientific advisors. Eighteen months later, the confirmatory trial failed — the drug performed no better than placebo.¹² The manufacturer pulled it from the market in April 2024. Annual list price had been $158,000.

Tofersen (Qalsody) was approved in April 2023 for the roughly two percent of ALS patients with a specific genetic variant. Its main trial also failed — the drug did not improve patients clinically.¹³ The FDA approved it anyway, on the basis that it reduced a chemical marker in the blood. Whether reducing that marker translates to patients living longer or better has not been demonstrated. List price: approximately $159,000 per year. Seven percent of patients in the trial developed serious neurological side effects, including inflammation of the spinal cord.

Riluzole — thirty years old, with about ten weeks of survival benefit — still defines the standard of care.

The Ice Bucket Challenge of 2014 raised approximately US$115 million for the ALS Association alone, with global donations across all ALS charities estimated at around US$220 million.¹⁴ ALSA committed approximately US$89 million of its share to research across more than five hundred projects. The main genetic deliverable a decade later is the discovery of NEK1 as a risk gene, with therapeutic implications still preclinical. The main therapeutic deliverables are tofersen and Relyvrio.

A century and a half of institutional research has not closed the question of what causes the disease. The question has been answered in ways the institutions cannot say out loud.

---

What Motor Neurons Are and How They Die

Motor neurons carry signals from the brain to the muscles. They tell the hand to wave and the leg to walk. The upper motor neurons sit in the motor cortex of the brain. The lower motor neurons sit in the anterior horn of the spinal cord. The corticospinal tract connects them. A signal originates upstairs, descends the cord, hands off in the anterior horn, and travels out to the muscle.

In motor neuron disease, both populations die. The hands weaken. The arms waste. The legs follow. Speech slurs as the muscles of the tongue and throat fail. Swallowing becomes difficult, then impossible. Finally the diaphragm — itself a muscle controlled by motor neurons in the cervical spinal cord — gives out. The patient dies because the muscle that pulls air into the lungs stops being told to do its job.

At autopsy, the lateral columns of the spinal cord show hardening — sclerosis, in the literal Latin sense of the word. The anterior horn cells are gone. The motor cortex shows neuronal loss. This is the picture Charcot saw in 1869 and named, accurately, after what was visible: amyotrophic (muscle wasting) lateral sclerosis (hardening of the lateral columns).

Herbert Shelton, writing on multiple sclerosis in the same anatomical neighborhood, observed that the sclerosis is the end-point of a much longer process:

“The trouble does not start as a sclerosis (hardening), but as an inflammation. A man dies after suffering with multiple sclerosis for fifteen or twenty years and an autopsy is performed. His brain and nervous system are subjected to the closest scrutiny and certain pathological changes are found. But this is the end-point. What was the condition of his nerves five years, ten years or fifteen years prior to death?”¹⁵

The same logic applies to the lateral sclerosis of motor neuron disease. By the time the pathologist sees the hardening, the damage has been accumulating for years. Inflammation that resolves heals the tissue. Inflammation that cannot resolve — because the insult continues — eventually produces sclerosis. The body responds to repeated injury until the cells responsible can no longer be repaired and the tissue hardens into scar.

In the terrain framework, the categories of insult that drive this process are toxic exposure, nutritional deficiency, electromagnetic radiation, and psychological strain.¹⁶ For motor neuron disease, toxic exposure dominates, with the others compounding it. The body cannot indefinitely repair anterior horn cells that are being poisoned, struck, or injected with neurotoxic substances faster than repair can keep pace.

---

The Convergence on Anterior Horn Cells

Three lines of evidence — chemical, mechanical, and injection — converge on the same cells, dying in the same way.

The DDT Line

In 1944 and 1947, R.D. Lillie and colleagues at the National Institutes of Health published findings that DDT exposure produced degeneration of the anterior horn cells of the spinal cord in animals.¹⁷ These are the same cells that die in motor neuron disease. The studies were quietly stopped.

Morton Biskind, an endocrinologist, recognized what the NIH data meant. Throughout the late 1940s and 1950s, DDT was being sprayed across American homes, schools, and farms. Biskind documented a parallel rise in paralytic illness that was being attributed to a virus called polio. He testified before Congress that a substantial fraction of what was being diagnosed as polio was DDT neurotoxicity targeting the same spinal cord cells that the NIH studies had already shown were vulnerable to the chemical:

“Particularly relevant to recent aspects of this problem are neglected studies by Lillie and his collaborators of the National Institutes of Health, published in 1944 and 1947 respectively, which showed that DDT may produce degeneration of the anterior horn cells of the spinal cord in animals. These changes do not occur regularly in exposed animals any more than they do in human beings, but they do appear often enough to be significant. When the population is exposed to a chemical agent known to produce in animals lesions in the spinal cord resembling those in human polio, and thereafter the latter disease increases sharply in incidence and maintains its epidemic character year after year, is it unreasonable to suspect an etiologic relationship?”¹⁸

Biskind’s career was destroyed. The viral narrative prevailed.

The relevance for motor neuron disease is direct. Organophosphate pesticides work via the same target Biskind documented: they inhibit cholinesterase, the enzyme that breaks down acetylcholine at the neuromuscular junction. Russell Blaylock explains the mechanism:

“When cholinesterase is deactivated, acetylcholine over-stimulates muscles, resulting in an inability to control movements.”¹⁹

Sustained organophosphate exposure produces what toxicologists call “organophosphate-induced delayed neuropathy” — a syndrome of progressive motor weakness with anterior horn cell pathology that is clinically and pathologically difficult to distinguish from motor neuron disease.

Mark Purdey, the English organic farmer who solved the BSE puzzle when the establishment couldn’t, demonstrated this principle in cattle. Phosmet, an organophosphate, was applied directly to the necks of British cattle from 1985 in a uniquely concentrated formulation. The chemical penetrated the skin and reached the brain. The cattle developed the neurological collapse the establishment called mad cow disease. Cattle on fully converted organic farms, which received the same feed but not the phosmet, did not develop the condition.²⁰ The Agricultural Health Study and follow-on meta-analyses have documented elevated motor neuron disease rates in pesticide applicators across multiple populations and decades — pooled odds ratios around 1.8.²¹

The DDT line is not historical. The chemical class that killed anterior horn cells in 1944 remains in widespread use. The populations most exposed to it develop motor neuron disease at elevated rates.

The Trauma Line

Lou Gehrig played fifteen full seasons in a sport that, in his era, painted its stadiums with lead and sprayed its outfields with lead arsenate as an insecticide. There were no helmets. Gehrig took thousands of impacts from fastballs, base collisions, and outfield walls.

At least four distinct loss-of-consciousness incidents are documented in the contemporaneous press accounts compiled by Jonathan Eig and other Gehrig biographers: a 1924 brawl with Ty Cobb in which Gehrig swung, missed, fell, and struck his head on concrete; a September 1930 game in which a ground ball hit him in the face at first base and knocked him out; a June 1934 exhibition game in Norfolk, Virginia in which Detroit pitcher Earl Whitehill beaned him above the right eye and left him unconscious for approximately five minutes — Gehrig played the next day wearing one of Babe Ruth’s larger caps to fit over the swelling; and a 1935 collision with an oncoming runner at first base.¹ He had earlier played fullback at Commerce High School in Manhattan and at Columbia University, in an era without meaningful head protection. The era’s medicine had no framework for taking a player out of a game for cognitive recovery. Concussions were “having one’s bell rung” and the standard treatment was smelling salts. Gehrig played 2,130 consecutive games over fourteen seasons, and subconcussive impacts accumulated across every one of them.

Then there were the chemicals. Lead arsenate was the standard insecticide on American baseball fields from the 1900s through the 1940s, when DDT replaced it. It does not biodegrade; lead and arsenic both persist in soil for decades. Gehrig spent fifteen years on outfields sprayed with lead arsenate continuously since before his birth. Stadium woodwork was finished in lead-based paint. The clubhouse plumbing was lead. Tetraethyl lead entered American gasoline in 1923 and saturated the urban air of Yankee Stadium and the road parks throughout Gehrig’s playing career.

His symptoms began in 1938. By spring training 1939 he was visibly stumbling. He pulled himself from the lineup on 2 May 1939. The Mayo Clinic delivered the diagnosis on 19 June 1939 — his thirty-sixth birthday. He was dead by 2 June 1941. Two years from diagnosis to death is approximately the median survival for sporadic ALS. By the metrics of his own disease, Gehrig’s trajectory was unremarkable. Only his biography is.

Chronic traumatic encephalopathy was not a recognized category when Gehrig died. By the time Bennet Omalu identified CTE in NFL players in the mid-2000s, the connection to motor neuron disease had begun to emerge in the establishment’s own neuropathology. Italian footballer cohort studies documented ALS incidence among Italian Serie A and B professional players running at six and a half times the rate of matched controls, with a dose-response by length of career and a positional concentration in midfielders.²² No basketball player in the same comparator population developed ALS. No cyclist did. The risk concentrated in the players who spent the most years on the most heavily treated turf, taking the most repeated head impacts, in the doping context that the Turin prosecutor Raffaele Guariniello eventually documented at length in his inquiry into Italian professional football. The NFL pattern matches: Lehman and colleagues at NIOSH, examining 3,439 retired NFL players, found combined Alzheimer’s and ALS mortality at roughly four times the expected rate, concentrated in “speed positions” whose careers involved the highest frequency of head-on collisions.²³ Scottish professional soccer players showed similar excess MND mortality.

In 2010, Ann McKee and colleagues at Boston University examined twelve cases of confirmed CTE and found that three of those athletes had also developed a progressive motor neuron disease — profound weakness, atrophy, spasticity, fasciculations — in the years before death. McKee coined a new term, chronic traumatic encephalomyelopathy (CTEM), to describe what they had found. Asked about Gehrig in an interview at the time, she said: *”We will never know whether Lou Gehrig had sporadic ALS or CTEM.”*²⁴

McKee is the establishment’s own leading CTE neuropathologist, telling the public on the record that the diagnostic line between sporadic ALS and trauma-related motor neuron disease cannot be drawn for athletes with extensive head-injury histories. Whatever the institution calls the resulting condition — ALS, CTEM, something else — the cells died from accumulated insult.

Other named cases follow the pattern. Steve Gleason. Tim Shaw. Kevin Turner, eight NFL seasons at fullback, autopsy confirming both CTE and motor neuron pathology. Dwight Clark. O.J. Brigance. Wally Hilgenberg, one of McKee’s three index cases. The establishment will accept the trauma-CTE link because it implicates a sport, not a pharmaceutical product. The extension to motor neuron disease has been documented but not used to drive the framework. The streetlight does not shine that direction.

Gehrig was cremated. No tissue exists. His Mayo Clinic records remain sealed under patient confidentiality; in 2012, a Minnesota legislator introduced a bill to unseal them and the institution declined. The case for re-examining what killed him is strong. The case for confirming it definitively is closed by an absence of tissue and an institution that will not release the paper trail.

The Injection Line

Charles Richet won the 1913 Nobel Prize for demonstrating that injection of foreign proteins creates sensitisation — that the body responds with increasing intensity to subsequent exposures with the same material.²⁵ This is the foundational discovery on which the entire concept of what medicine now calls “autoimmunity” rests. The injection mechanism was scrubbed from the literature in the decades that followed, leaving only the appearance of mysterious self-attack. Richet had described the actual sequence: exposure, sensitisation, escalating response, eventually tissue damage at the site the body is now reacting to.

The Gulf War cluster is Shaw’s case study, and it closes the door on every alternative explanation the establishment offers for the rising tide of motor neuron disease.

Roughly 697,000 American soldiers served in the 1990–1991 Gulf War. Approximately 250,000 of them — about thirty-six percent — developed a debilitating multi-symptom illness that came to be called Gulf War Syndrome.²⁶ The exposures the Department of Veterans Affairs eventually acknowledged include: the anthrax vaccine and an unusually compressed vaccination schedule (some soldiers received ten or more vaccines in days); pyridostigmine bromide, an acetylcholinesterase inhibitor distributed as a prophylactic against nerve gas; organophosphate pesticides applied to uniforms, tents, and skin; depleted uranium from armor-piercing ammunition; oil well fire smoke; possible low-level sarin from the demolition of Iraqi weapons depots at Khamisiyah.

Initial military response was to blame stress. When the stress hypothesis collapsed under the obvious objection that soldiers who had not seen combat were getting sick at the same rates as those who had, the official line shifted to “multi-factorial” — meaning that no single cause would be named. Contradictory studies were funded. Veterans were told their condition was idiopathic. Robert Malone, summarising the response, put it this way: “the military gaslighted the veterans by insisting that the illness was due to stress (which for many reasons was nonsensical), and then introduced a variety of contradictory studies to explain what else could be causing GWS.”²⁶

Motor neuron disease appeared in the Gulf War cohort at elevated rates and at younger ages than usual. Robert Horner and colleagues at Duke University, working under VA funding, examined the records of around 2.5 million American veterans from the era. Soldiers who had deployed to the Gulf were getting ALS at roughly twice the rate of soldiers who had not.²⁷ Air Force veterans were the worst hit, running at nearly three times the rate. A separate Harvard study, drawing on a long-running American Cancer Society cohort of more than half a million men, found that anyone who had served in any branch of the military, in any era, died of ALS at about one and a half times the rate of men who had never served.²⁸ Coast Guard veterans died at more than twice the civilian rate.

The institutional response went further than the public statements. In December 2001, the VA Secretary announced disability benefits for Gulf War veterans with ALS. In November 2006, the Institute of Medicine concluded that the evidence supported an association between military service and ALS. In September 2008, the VA published an interim final rule establishing a presumption of service connection for ALS for any veteran with at least ninety days of active service. The rule, codified at 38 CFR §3.318, reads in its operative section: “The development of amyotrophic lateral sclerosis manifested at any time after discharge or release from active military, naval, air, or space service is sufficient to establish service connection for that disease.”²⁹ Any veteran. Any time after discharge. The VA accepts the link strongly enough to write the presumption into federal regulation, and has never publicly named what causes the disease.

Shaw’s epidemiological observation rules out everything but the injection. Soldiers who were vaccinated in preparation for deployment but never deployed — who never breathed oil well smoke, never touched depleted uranium, never sprayed their tents with permethrin, never approached Khamisiyah — got the same syndrome at the same elevated rates.³ The chemical exposures could not reach them. The vaccine did. The illness also appeared in soldiers vaccinated nearly a decade later, after the war was long over, with the same anthrax product.³⁰ Coalition forces from nations that did not vaccinate their troops did not experience the syndrome.³⁰ The variable that tracks with the disease across these subgroups is the vaccine, not the battlefield.

The manufacturer was BioPort, a Michigan-based company purchased in 1998 by Lebanese-born financier Fuad El-Hibri and his father Ibrahim, in partnership with retired Admiral William Crowe Jr., former chairman of the Joint Chiefs of Staff under Presidents Reagan and George H.W. Bush. They paid Michigan twenty-five million dollars for the aging vaccine plant. Within a month of taking control, BioPort had signed an exclusive twenty-nine million dollar contract with the Pentagon to manufacture and supply anthrax vaccine for American troops. The Secretary of the Army indemnified the factory the day before the contract was signed.³¹

An FDA audit ten months before the purchase had documented contamination, security breaches, suspect record-keeping, and nine million stored doses found to be adulterated. The plant could not pass an FDA audit even after the purchase. BioPort received additional federal funds to rebuild the facility from scratch and still could not pass inspection. The company was in a death spiral toward bankruptcy by mid-2001 when the October 2001 anthrax letter incidents arrived to rescue them.³¹

Meryl Nass, the physician who has tracked the anthrax vaccine program more closely than anyone else in medicine, identified the most probable mechanism. The vaccine was manufactured in a rushed, dirty process. To meet deployment timelines, BioPort substituted larger filters that did not clog but also no longer effectively purified the final product, and failed to notify the FDA of the change. The doses that reached American soldiers were among the most contaminated pharmaceutical products ever distributed at scale to a captive population. BioPort eventually rebranded as Emergent BioSolutions, which later manufactured Johnson & Johnson’s COVID-19 vaccine and was ordered by the FDA to destroy millions of improperly produced doses in 2021.³¹

Shaw’s aluminum hypothesis and Nass’s dirty-manufacture hypothesis are not in competition. The vaccine contained an aluminum adjuvant that injection toxicology has demonstrated produces motor neuron damage in animal models. It was also manufactured in conditions that introduced additional contaminants. The squalene controversy — documented in the book Vaccine A, with antibody tests showing Gulf War veterans had developed antibodies to squalene matching a dose-response pattern — adds another line to the inventory of what the soldiers were injected with.³²

Christopher Exley, professor of bioinorganic chemistry at Keele University, has documented that injected aluminum is transported from injection sites throughout the body and reaches the brain in amounts the ingested route never produces.³³ Russell Blaylock notes the contrast directly: gastrointestinal absorption of aluminum runs around 0.1 percent with rapid excretion; intramuscular injection produces approximately 100 percent absorption, with macrophages then distributing the metal throughout the body over months and years.³³ The standard institutional defense — that we eat more aluminum than we inject — compares an exposure route the body handles to an exposure route it does not.

Yehuda Shoenfeld and colleagues have named the resulting clinical pattern ASIA syndrome — autoimmune/inflammatory syndrome induced by adjuvants.³⁴ The literature contains documented cases of motor neuron disease and ALS-like syndromes following vaccination.

Every serious investigator of Gulf War Syndrome — Shaw, Nass, the squalene researchers, the mycoplasma-contamination hypothesis — points at the injection. The mechanism details differ. The agent does not. The Pentagon paid the disability claims. The VA wrote the service-connection rule into federal regulation. The institutional behaviour acknowledges what the institutional public statements do not.

The establishment has admitted causation for occupational populations it cannot deny — paying the Gulf War claims, funding the Agricultural Health Study, accepting the CTE-trauma link in football. It will not extend the framework to the general population because doing so implicates products, procedures, and an entire agricultural-chemical economy. The streetlight illuminates the populations whose disease can be paid off as occupational injury, and leaves the rest of the picture in the dark. The general public, exposed at lower doses to the same chemical classes and the same injection schedule, is told the cause is unknown.

Speaking the cause implicates the products and procedures the framework was built to protect.

---

What Can Be Done

The terrain framework offers an actionable response where the establishment offers only diagnosis. The interventions below proceed from the principle that the body is built to repair itself when the insults stop and the repair substrate is present.

Stop adding to the load. No further injections. This is the single most consequential decision for anyone with a diagnosis or anyone at elevated risk — pesticide applicators, military veterans, contact-sport athletes, welders, anyone with an exposure history. Aluminum, once injected, accumulates over months and years. Each subsequent injection adds to a body burden the kidneys cannot eliminate.

Audit the pharmaceutical intake. Statins lower cholesterol — and cholesterol is the molecule that builds myelin and stabilizes neuronal membranes. Anticholinergics block the same neurotransmitter pathway that organophosphates damage. Anything crossing the blood-brain barrier with known neurological side effects deserves scrutiny against the question: does the benefit warrant the cost in nervous-system repair capacity?

Remove what is already there. Dental amalgams are mercury, and mercury is a documented neurotoxin. Removal under proper protocol (the Huggins approach) eliminates an ongoing source of exposure. Heavy metal chelation under terrain-paradigm practitioner supervision can reduce stored burden. Address the body’s detoxification capacity through whole-food nutrition rather than industrial synthetic substitutes.

Reduce ongoing exposure. Organic food eliminates the daily microdose of organophosphates, glyphosate, and 2,4-D. Filtered water reduces fluoride, aluminum, and chlorination byproducts. Avoid the synthetic fragrance and personal-care product load. Reduce non-native electromagnetic exposure where possible — distance from routers and cell phones, wired connections where practical, time outside the building.

Feed the repair process. Nutrient-dense whole foods. Pasture-raised animal products, organ meats, bone broth, traditional fats. Sunlight on the skin daily. Adequate sleep. The work of Weston Price, Sally Fallon, and the Weston A. Price Foundation provides the practical framework. Marizelle Arce and other terrain-paradigm naturopaths have documented dietary protocols specifically supporting nervous system repair.

Consider therapeutic fasting under supervision. Herbert Shelton documented multiple sclerosis recoveries through extended water fasting in cases conventional neurology had categorized as hopeless.³⁵ The mechanism — clearing toxic burden, allowing energy normally spent on digestion to be redirected to repair — applies equally to motor neuron pathology when caught early. Shelton’s protocol: a first fast producing measurable increase in limb control; rest in bed following; sunbathing; a second fast adding further control; sometimes a third. Shelton’s qualification still applies: “It is in the initial stage that full recovery is or should be possible, not in the advanced stages when irreversible changes in the nerve structures have taken place.” Fasting at this depth is not a self-administered intervention. The Hygienic tradition operated through residential institutions where supervised water fasts of thirty to sixty days were routine.

Examine the documented recoveries. Richard Bedlack at Duke University maintains a registry of ALS reversals — patients who recovered or stabilized when conventional treatment said they should not have. The registry contains patients who substantially improved on protocols ranging from dietary intervention to off-label experimentation. These cases are dismissed as anomalies in the establishment framework because the framework has no place for terrain change driving disease reversal. Under the terrain framework they are exactly what should be expected when toxic load drops below the threshold of damage.

Consider what crosses the blood-brain barrier. Pharmaceutical compounds, glyphosate residues on food, and certain food additives breach the blood-brain barrier in ways the body cannot easily counter. Aspartame metabolizes to methanol, then to formaldehyde, then to formic acid — the last two acutely neurotoxic. Russell Blaylock has called aspartame an axon poison; methanol affects identical sites in the brain to those damaged in multiple sclerosis.³⁶ MSG and free glutamate produce excitotoxicity — neurons firing themselves to death when overstimulated.

Address the emotional and psychological dimension. The fourth category of insult is psychological strain — sustained stress physiology that suppresses the body’s restorative processes. Motor neuron disease arrives, frequently, in patients whose prior decades involved sustained high-intensity work, suppression of emotion, denial of fatigue. The pattern is not deterministic but appears frequently enough that the terrain framework cannot ignore it. Whatever interventions reduce sustained stress physiology — meditation, breathwork, time in nature, resolution of long-suppressed emotional material, the willingness to rest — belong in the protocol. The body cannot repair while in chronic alarm.

Not all cases recover. The earlier the intervention, the better. Shelton’s principle holds — the inflammatory stage is remediable; the late hardening is not. By the time the diagnosis arrives, years of repair have already been refused. This is the cruelty embedded in the establishment delay. The reader who has just heard the diagnosis has less time than someone who acts in response to family history or occupational risk.

---

Lou Gehrig

Lou Gehrig hit 493 home runs in a sport that painted its stadiums with lead and sprayed its outfields with lead arsenate. He took thousands of impacts to the head over fifteen seasons without a helmet. He retired at thirty-six having visibly deteriorated for two years. He died at thirty-seven of a condition the establishment still calls a mystery.

They named the condition after him.

The exposures he absorbed are on the public record. The mechanisms by which those exposures kill motor neurons have been demonstrated in animals and documented in human populations. Naming the condition after the patient honoured the man and buried what killed him.

---

Explain It To A 6 Year Old

Motor neurons are wires that carry messages from your brain to your muscles. They tell your hand to wave and your leg to walk. In motor neuron disease, these wires stop working. The messages cannot get through. The muscles cannot move. After a while, the muscles get smaller and weaker because they are not being used.

Doctors say they do not know what causes it. But we know some things that hurt these wires.

Bug sprays hurt them. Heavy metals like lead and mercury hurt them. Getting hit in the head a lot hurts them. Putting strange things into your body through needles hurts them.

Soldiers who got lots of injections during a war got this disease. Footballers who got hit in the head a lot and played on grass sprayed with bug poisons got this disease. Farmers who worked with bug poisons for years got this disease. The same wires get damaged in all of them.

A famous baseball player called Lou Gehrig got the disease and died when he was thirty-seven. He played on fields painted with lead and got hit in the head a lot. Doctors named the disease after him. They did not say what made him sick.

If someone has this disease, the most important thing is to stop putting more poisons in. Eat real food that grew in good soil. Drink clean water. Sit in the sun. Sleep enough. The body wants to fix itself. Stop hurting it, and give it a chance.

---

References

1. Eig, J. (2005). Luckiest Man: The Life and Death of Lou Gehrig. Simon & Schuster. Documented concussion incidents and timeline of symptom onset.

2. Goetz, C. G. (2000). Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle & Nerve, 23(3), 336–343.

3. Shaw, C. A. (2021). Dispatches from the Vaccine Wars: Fighting for Human Freedom During the Great Reset. Skyhorse Publishing. Account of the Gulf War ALS cluster and the non-deployed cohort epidemiology.

4. Shaw, C. A., & Petrik, M. S. (2009). Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. Journal of Inorganic Biochemistry, 103(11), 1555–1562.

5. Mayo Clinic. Amyotrophic lateral sclerosis (ALS) – Symptoms and causes. mayoclinic.org (accessed May 2026).

6. ALS Association. ALS Risk Factors. als.org/research/our-awards-and-programs/impact-our-funding/als-research-topics/biomarkers/als-risk-factors

7. Motor Neurone Disease Association UK. What causes MND. mndassociation.org/about-mnd/mnd-explained/what-causes-mnd

8. ALS Association. ALS Genetics. als.org/research/als-research-topics/genetics. The four named genes account for approximately 70% of familial ALS, which represents approximately 10% of total cases.

9. Mehta, P. et al. (2022). Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(1-2), 108–116.

10. Andrews, J. A. et al. (2020). Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. See also Fang, T. et al. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurology, 17(5), 416–422.

11. Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, 16(7), 505–512.

12. Amylyx Pharmaceuticals. SEC Form 8-K, 8 March 2024, reporting PHOENIX Phase 3 trial results (p=0.667). Market withdrawal announced 4 April 2024. FDA withdrawal of approval published 29 August 2025 (Federal Register Document 2025-16646).

13. Miller, T. M. et al. (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387, 1099–1110. Primary endpoint p=0.97. FDA accelerated approval granted 25 April 2023 on plasma neurofilament light chain biomarker.

14. Reardon, S. (2017). Fundraising: The Ice Bucket Challenge delivers. Nature, 550, S113. See also ALS Association IBC commitments page at als.org/IBC/commitments.

15. Shelton, H. M. (1964). Multiple Sclerosis, in Fasting Can Save Your Life. American Natural Hygiene Society.

16. Lester, D., & Parker, D. (2019). What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. Independently published.

17. Lillie, R. D., & Smith, M. I. (1944). Pathology of experimental poisoning in cats, rabbits, and rats with 2,2-bis(parachlorphenyl)-1,1,1-trichlorethane. Public Health Reports, 59(31), 979–984.

18. Biskind, M. S. (1953). Public health aspects of the new insecticides. American Journal of Digestive Diseases, 20(11), 331–341. Quoted in Cowan, T. S., & Fallon Morell, S. (2020). The Contagion Myth. Skyhorse Publishing.

19. Blaylock, R. (2006). Health and Nutrition Secrets. Health Press. Quoted in Lester & Parker.

20. Purdey, M. (2007). Animal Pharm. Clairview Books. See also Engelbrecht, T., Köhnlein, C., & Bailey, S. (2021). Virus Mania, 3rd edition.

21. Kamel, F. et al. (2012). Pesticide exposure and amyotrophic lateral sclerosis. NeuroToxicology, 33(3), 457–462. Pooled OR for pesticide exposure and ALS approximately 1.8.

22. Chiò, A. et al. (2005). Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 128(Pt 3), 472–476. SMR 6.5 (95% CI 2.1–15.1); dose-response with career duration. See also Belli, S., & Vanacore, N. (2005). Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? European Journal of Epidemiology, 20(3), 237–242. SPMR 11.58.

23. Lehman, E. J. et al. (2012). Neurodegenerative causes of death among retired National Football League players. Neurology, 79(19), 1970–1974. Combined Alzheimer’s/ALS mortality in NFL retirees approximately 4× general population for speed-position players. See also Mackay, D. F. et al. (2019). Neurodegenerative Disease Mortality among Former Professional Soccer Players. New England Journal of Medicine, 381, 1801–1808.

24. McKee, A. C. et al. (2010). TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. Journal of Neuropathology and Experimental Neurology, 69(9), 918–929. Three of twelve CTE cases also developed motor neuron disease. McKee’s “We will never know” quote drawn from her contemporaneous Boston University and NPR interviews surrounding publication. Mayo Clinic records sealing referenced in Phyllis Kahn’s 2012 Minnesota legislative initiative.

25. Richet, C. (1913). Anaphylaxis. Liverpool University Press. Nobel Prize lecture, 1913.

26. Malone, R. (2023). The First Mandatory Vaccination Campaign That Crippled America’s Pilots. Substack publication on Gulf War Syndrome incidence and the anthrax vaccine program.

27. Horner, R. D. et al. (2003). Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology, 61(6), 742–749. Deployed personnel RR=1.92 (95% CI 1.29–2.84). Air Force RR=2.68.

28. Weisskopf, M. G. et al. (2005). Prospective study of military service and mortality from ALS. Neurology, 64(1), 32–37. Veterans RR=1.53 (95% CI 1.12–2.09).

29. US Code of Federal Regulations, Title 38, Part 3, §3.318. Presumption of service connection for amyotrophic lateral sclerosis. Original interim final rule published 23 September 2008 at 73 FR 54691; final rule published 4 November 2009 at 74 FR 57072. Based on the November 2006 Institute of Medicine report Amyotrophic Lateral Sclerosis in Veterans.

30. A Midwestern Doctor. (2023). We Now Have Key Evidence Pfizer Committed Fraud. Substack publication including discussion of Gulf War Syndrome in non-deployed vaccinated soldiers and in coalition forces that did not vaccinate.

31. Kennedy, R. F. Jr. (2021). The Real Anthony Fauci. Skyhorse Publishing. Chapter on BioPort, the El-Hibri family, the Michigan plant acquisition, FDA audit failures, and the post-2001 anthrax letters bailout.

32. Matsumoto, G. (2004). Vaccine A: The Covert Government Experiment That’s Killing Our Soldiers. Basic Books. Documentation of squalene antibody testing in Gulf War veterans and the dose-response pattern in BioPort lots.

33. Exley, C. (2016). The toxicity of aluminium in humans. Morphologie, 100(329), 51–55.

34. Shoenfeld, Y., & Agmon-Levin, N. (2011). ‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants. Journal of Autoimmunity, 36(1), 4–8.

35. Shelton, H. M. Fasting Can Save Your Life. Chapter 20: Multiple Sclerosis. Documented recovery cases under extended therapeutic fasting.

36. Monte, W. C. (2012). While Science Sleeps: A Sweetener Kills. Wood Publishing. Documentation of methanol from aspartame as an axon poison and the overlap of methanol-damage sites with multiple sclerosis lesions. See also Blaylock, R. Excitotoxins: The Taste That Kills.